Tonix Pharmaceuticals is currently seeking participants for a new medical research study (the AFFIRM Study). The study is for an investigational new medication (Tonmya) that may help treat the symptoms of fibromyalgia. The study is limited to 500 participants and is designed to test the safety and efficacy of Tonmya taken daily at bedtime for 12 weeks to treat fibromyalgia and improve sleep quality.
“People are beginning to understand that fibromyalgia is not just a pain disorder,” says Tonix CEO Dr. Seth Lederman. “If we can improve the sleep quality in fibromyalgia patients, then their other symptoms will improve also.”
Participants will receive all study-related care at no cost, and your fibromyalgia condition and overall health will be closely monitored by a team of physicians and study staff. As a study participant, you will be asked to meet with your study doctor approximately 6 times over a 3-4 month period to provide feedback about your experiences. You may also be compensated for your time and travel to attend these visits.
To qualify, you must be between 18 and 75 years old and diagnosed with fibromyalgia. After taking an online pre-screening questionnaire, potential participants will be referred to a study center. Following is a list of the AFFIRM study center locations by state: Alabama (Birmingham), Arizona (Phoenix), California (Sacramento, San Diego), Florida (Brandon, Deland, Lakeland, Ocala, Orlando, Tampa, West Palm Beach), Georgia (Columbus, Smyrna), Indiana (Evansville), Massachusetts (North Dartmouth), Michigan (Ann Arbor), Mississippi (Jackson), New York (Williamsville), Ohio (Cincinnati, Cleveland), Oregon (Medford, Portland), Pennsylvania (Allentown), Rhode Island (Warwick), South Carolina (Greer, Mount Pleasant), Texas (Dallas), Utah (Salt Lake City), Washington (Bellevue, Seattle), Wisconsin (Kenosha), Virginia (Norfolk).
For more information and to find out if you qualify, visit http://www.affirmstudy.com/index.htm. For more technical details about the study, visit https://clinicaltrials.gov/ct2/show/NCT02436096